DrArturo AI
Augmented Intelligence Chatbot
DrArturo AI comes into play when a patient is deemed eligible for more specific information about clinical trials. He offers detailed insights about individual trials, as if he were a physician explaining the intricacies to a patient.
DrArturo AI Provides
- In-depth trial information
- Molecule and treatment details
- Schedule of events
- Nearest treatment facility
- Insurance acceptance and much more
For referring physicians, DrArturo AI delivers advanced knowledge about potential trials for their cancer patients. He offers logistical information, trial details, and contact information to facilitate collaboration between physicians and trial coordinators.
For site principal investigators and research coordinators, DrArturo AI is a versatile tool that can be activated for potential eligible and/or enrolled patients in unique trials. He is capable of:
- Explaining in-depth details about the study
- Answering simple and highly advanced questions about the protocol
- Providing access to key documents and schedule of events
- Triggering patient-reported outcomes and adverse events to the research team when mentioned by the patient
- Our ChatGPT-powered chatbot platform is designed to streamline the clinical trial process for all parties involved, fostering understanding, collaboration, and ultimately, better patient outcomes.
DrArturo AI - Key Features
- Expert and professional persona:
- Knowledgeable and authoritative, providing reliable information
- Designed to instill confidence in patients and healthcare professionals
- In-depth clinical trial information:
- Detailed trial descriptions, including objectives, treatments, and outcomes
- Molecule and treatment-specific information to support decision-making
- Customizable to any trial, sponsor, molecule or research program, and institution
- Adaptable to local standard of care testing and regional treatment options to support decision-making
- Personalized trial recommendations:
- Analyzes user data to identify potentially suitable clinical trials
- Tailors suggestions to individual needs and circumstances
- Schedule of events and logistics:
- Provides trial timelines, appointment scheduling, and important dates
- Shares information on the nearest treatment facilities and insurance acceptance
- Collaboration with referring physicians:
- Offers advanced trial knowledge for physicians seeking options for their patients
- Facilitates communication between physicians and trial coordinators
- Support for site principal investigators and research coordinators:
- Activates chatbot for eligible or enrolled patients in unique trials
- Answers questions about protocols, study details, and key documents
- Patient-reported outcomes and adverse events:
- Triggers alerts to the research team when patients mention outcomes or adverse events
- Supports timely response and intervention by clinical teams
- Fully aligned with known AEs from standard or care, if applicable, and CTCAE criteria
- User-friendly interface:
- Intuitive, easy-to-navigate layout optimized for various devices
- Seamless integration with existing systems and platforms
- Multilingual support:
- Communicates with users in multiple languages to increase accessibility
- Real-time assistance:
- Provides immediate and accurate responses to user inquiries
- Enhances the efficiency and convenience of information access
- Adaptive learning:
- Utilizes machine learning algorithms to continuously refine its knowledge base
- Keeps up to date with the latest advancements in cancer clinical trials
- Data privacy and security:
- Adheres to data protection regulations and maintains user confidentiality
- Safeguards sensitive information with robust security measures
US / Out US Patients
Sponsored Clinical Trials
Clinical Trials for Pre-Screening
Countries
Global Partners
About Massive Bio
Massive Bio empowers cancer patients to find their best treatment options, using artificial intelligence to improve equitable access and precision targeting for clinical trial matching, drug matching, and drug development. Massive Bio combines its best-in-class AI platform with technology-enabled services to remove barriers in clinical trial enrollment, value-based oncology decisions, and data-driven cancer treatment. The company serves more than two dozen pharmaceutical companies, contract research organizations, and hospital networks, and has been awarded an SBIR contract by the National Cancer Institute. Massive Bio was founded in 2015 by clinical, technology, and M&A executives, and has a global presence with nearly 100 people in 12 countries.